Herborium Group's Second Quarter Sales Grows over 132%
July 17 2014 - 8:30AM
Fort Lee, N.J. July 16, 2014 Herborium® Group, Inc. (OTC
Pink: HBRM), www.Herborium.com, a Botanical Therapeutics®
Company and the provider of unique all botanical medicinal
products (Botanical Therapeutics®) that target dermatological
problems such as acne, and other health and wellness concerns
in the areas of sexual performance as well as energy
depletion and stress, reports that its sales
for the Second Quarter of 2014 grew by 132
% in comparison to the same period of 2013. This puts the present
run rate for AcnEase® sales for 2014 to exceed $1 million
dollars. .
During the first six months (ending 5/31/2014) of 2014,
Herborium's sales increased 86% in comparison to the same six month
period in 2013. The Company's Gross Profit increased 2.5 fold
and the loss from operations for the same period decreased
86%. The Company continues its expansion of AcnEase® in
French market and has also began penetrating Spanish and Spanish
speaking markets with a newly established Spanish
Website and related e-commerce strategy. The Company's Facebook
following is approaching 10,000 people.
Herborium remains very optimistic about growing its business,
sales and product awareness due to the steady growth of the
AcnEase® brand as well as its three new products that have already
generated interest and will enter the market this year. The
Company continues its efforts to decrease costs. While
still recognizing the expenses associated with developing and
launching new products and the associated upfront costs.
Herborium continues to retire debt, thus increasing the Company's
ability to raise outside funds at a reasonable cost. There is
a rising interest in Botanical Therapeutics® among consumers as
well as both the financial and medical communities that can serve
as a solid foundation for the company's promising
future.
These developments put the Company closer to
executing the up listing plan announced in
2013.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that
develops, license and markets proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Company business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses
clinical validation and a proactive regulatory strategy based on
the FDA Guidance for Industry: Botanical Drug Products (FDA
Guidance 2004) to establish and maintain a differential
advantage. Herborium has secured a pipeline of botanical
ingredients based products in the areas of dermatological needs,
wellness and energy, prostate health, women's health and selected
sexual disorders resulting from cardiovascular disease, use of
anti-depressants, diabetes, surgical procedures, and other
problems. Herborium Group sells its products in the United States,
the United Kingdom, and continental Europe through a network of
distributors, specialty retailers, and e-commerce. For more
information, please visit www.herborium.com, and
www.acnease.com.
Safe Harbor Statement: This release contains
forward-looking statements with respect to the results of
operations and business of Sunrise Consulting Group, Inc., which
involves risks and uncertainties. The Company's actual future
results could materially differ from those discussed.
The Company intends that such statements about the Company's future
expectations, including future revenues and earnings, and all other
forward looking statements be subject to the "Safe Harbors"
provision of the Private Securities Litigation Reform Act of
1995.
CONTACT: Dr. Agnes P. Olszewski
DrAgnes@Herborium.com
or
InvestorsRelations@Herborium.com
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Dec 2023 to Dec 2024